Hospira Reports Third-Quarter 20...( LAKE FOREST Ill. Oct. 27 /- Hospira I...),Health

LAKE FOREST, Ill., Oct. 27 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today reported results for the third quarter ended Sept. 30, 2009. Net sales for the quarter were $1.0 billion, and adjusted* diluted earnings per share were $0.90. (Adjusted* measures exclude certain specified items as described later in this press release and the attached schedules.)

"Hospira delivered strong results in the third quarter, aided by the launch of the generic oncolytic oxaliplatin and additional progress toward our Project Fuel initiatives," said Christopher B. Begley, chairman and chief executive officer. "We continued to position Hospira for future success in this milestone quarter, during which we surpassed the billion dollar revenue mark for the first time and generated strong double-digit earnings per share growth. We remain confident in our projections for full-year sales and are increasing our earnings per share guidance."

Third-Quarter 2009 Results

The following table highlights selected financial results for the third quarter of 2009 compared to the same period in 2008:

    In $ millions,              GAAP                     Adjusted*
     except per          Three Months Ended         Three Months Ended
     share amounts          September 30,              September 30,
                          ----------------     %     ----------------     %
                           2009      2008   Change    2009      2008   Change
                        --------    ------  ------   ------    ------  ------
    Net Sales           $1,007.5    $925.5    8.9%     n/a       n/a     n/a
    Gross Profit
     (Net Sales
     less Cost of
     Products Sold)       $395.6    $333.8   18.5%   $418.4    $355.5   17.7%
    Income from
     O
'/>"/>
SOURCE  Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
Related medicine technology :

1. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
2. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
3. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
4. Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov. 11
5. Hospira Names Daphne E. Jones Chief Information Officer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs